Liposome-containing composition for cosmetic and cosmetic

Abstract

The present invention provides: a liposome-containing composition for cosmetics, which contains gamma-aminobutyric acid and stably contains a fine liposome having a single-layer structure; and a cosmetic obtained by using the liposome-containing composition for cosmetics. Also provided are: a liposome-containing composition for cosmetics, which contains a liposome and water, and which is characterized in that: the liposome-containing composition for cosmetics contains at least one of a plurality of liposomes, a plurality of liposomes, and a plurality of liposomes; and a cosmetic which is obtained using the liposome-containing composition for cosmetics. The liposome contains gamma-aminobutyric acid, polyoxyethylene phytosterol, cholesterol, lecithin, and at least one compound (E) selected from the group consisting of a phytosterol fatty acid ester and a sphingosine base, and has a single-layer structure and an average particle diameter of 100 nm to 500 nm.

Description

Technical Field

[0001] This invention relates to a liposome-containing composition for cosmetic use and a cosmetic product. Background Technology

[0002] Liposomes are closed endoplasmic reticulum structures formed by a lipid bilayer membrane containing lipids such as lecithin, with an aqueous phase (internal aqueous phase) within the closed endoplasmic reticulum. Typically, liposomes exist as an aqueous solution dispersed outside the closed endoplasmic reticulum (external aqueous phase). Various inclusion components can be formulated into liposomes, and various liposome-containing cosmetic compositions containing various cosmetic ingredients, pharmaceutical ingredients, etc., have been proposed as inclusion components.

[0003] Patent Document 1 discloses a liposome-containing composition for cosmetic use, which contains liposomes and a dispersion medium for dispersing liposomes. The liposomes contain one or more compounds A selected from the group consisting of stearyl glycyrrhetinic acid ester, polyoxyethylene phytosterol, cholesterol and phytosterols other than the aforementioned polyoxyethylene phytosterol, and lecithin, and include liposomes having a monolayer structure.

[0004] Gamma-aminobutyric acid (GABA) is known to help prevent skin aging through vasodilation, promote collagen production, stimulate hair growth, and have whitening effects. Furthermore, information from raw material manufacturers indicates that GABA also promotes epidermal cell proliferation and hyaluronic acid production.

[0005] Patent Document 1: Japanese Patent Application Publication No. 2023-32103

[0006] Given the various effects of gamma-aminobutyric acid (GABA), there is a demand for its formulation in cosmetics. When applying GABA-containing cosmetics to the skin, there is a need for methods to more effectively deliver GABA into the skin. One such method is to encapsulate GABA in liposomes.

[0007] Liposomes consist of an endoplasmic reticulum (ER) and inclusions, the ER being formed by a lipid bilayer membrane. The morphology of liposomes includes membrane liposomes (also called single-lamellar vesicles) with a single-lamellar lipid bilayer and liposomes with a multi-lamellar lipid bilayer. From the viewpoint of being able to contain more γ-aminobutyric acid (GABA) as a water-soluble component and having excellent permeability into the skin, liposomes with a single-lamellar structure and a fine average particle size are preferred.

[0008] For example, Patent Document 1 describes a liposome-containing composition for cosmetic use, wherein the liposomes have a monolayer structure including a specific structure. However, it has been found that when γ-aminobutyric acid is formulated to form the liposomes with the monolayer structure described in Patent Document 1, the liposomes exhibit decreased formability and unstable liposomes with an average particle size that increases to an undesirable size. Summary of the Invention

[0009] The present invention was made in view of the above circumstances. One embodiment of the present invention aims to solve the problem of providing a liposome-containing composition for cosmetic use, which contains γ-aminobutyric acid and stably contains fine liposomes having a monolayer structure. In this invention, "fine" liposomes refer to liposomes with an average particle size of less than 500 nm. Furthermore, another embodiment of the present invention aims to solve the problem of providing a cosmetic product made using the above-described liposome-containing composition for cosmetics.

[0010] The present invention includes the following methods. [1] A cosmetic composition containing liposomes, comprising liposomes and water, wherein, The liposomes described above contain γ-aminobutyric acid, polyoxyethylene phytosterol, cholesterol, lecithin, and compound E, which is selected from at least one of the group consisting of phytosterol fatty acid esters and sphingosine bases, and contain liposomes with a monolayer structure and an average particle size of 100 nm to 500 nm. [2] According to the liposome-containing cosmetic composition described in [1], wherein, The ratio of γ-aminobutyric acid content to compound E content is 0.4 to 1000 on a mass basis. [3] The cosmetic liposome-containing composition according to [1] or [2], wherein, The ratio of γ-aminobutyric acid content to the total content of polyoxyethylene phytosterols, cholesterol and lecithin is 0.05 to 20.0 on a mass basis. [4] The cosmetic composition containing liposomes according to any one of [1] to [3] further contains ergothioneine. [5] A cosmetic product made using any one of [1] to [4] of a cosmetic composition containing liposomes. Invention Effects

[0011] According to one embodiment of the present invention, a liposome-containing composition for cosmetic use can be provided, which contains γ-aminobutyric acid and stably contains fine liposomes having a monolayer structure. Furthermore, according to another embodiment of the present invention, it is possible to provide a cosmetic product made using the above-described cosmetic composition containing liposomes. Detailed Implementation

[0012] Hereinafter, an example of an embodiment of the liposome-containing composition for cosmetics and the cosmetic product according to the present invention will be described in detail. However, the liposome-containing composition for cosmetics and the cosmetic product according to the present invention are not limited to the following embodiment, and can be appropriately modified and implemented within the scope of the purpose of the present invention.

[0013] In this invention, the numerical range represented by “~” includes the numerical values ​​recorded before and after “~”, which are respectively the minimum and maximum values. In the numerical ranges described in stages in this invention, the upper or lower limit value described in one numerical range can be replaced with the upper or lower limit value of other numerical ranges described in stages. Furthermore, in the numerical ranges described in this invention, the upper or lower limit value of that numerical range can be replaced with the values ​​shown in the embodiments. In this invention, each component may contain multiple corresponding compounds. When multiple substances corresponding to each component are present in the composition, unless otherwise specified, the content of each component represents the total content of the multiple substances present in the composition. In this invention, a combination of two or more preferred methods is a more preferred method. In this invention, "mass%" has the same meaning as "weight%", and "parts by mass" has the same meaning as "parts by weight". In this invention, "cholesterol" refers to the general term for sterols contained in animals, and "phytosterols" refers to the general term for sterols contained in plants. In this invention, "water solubility" means that the solubility in 100g of water at a liquid temperature of 22°C and pH 7.0 is greater than 0.1g.

[0014] Liposome-containing compositions for cosmetic use The cosmetic liposome-containing composition of the present invention contains liposomes and water. The liposomes contain γ-aminobutyric acid, polyoxyethylene phytosterol, cholesterol, lecithin, and compound E (hereinafter also referred to as "compound E"), which is at least one of the group consisting of phytosterol fatty acid esters and sphingosine bases. Furthermore, it comprises liposomes having a monolayer structure with an average particle size of 100 nm to 500 nm (hereinafter also referred to as "specific liposomes").

[0015] In addition, the following will sometimes refer to the γ-aminobutyric acid, polyoxyethylene phytosterol, cholesterol, lecithin and compound E contained in a particular liposome as component A, component B, component C, component D and component E, respectively.

[0016] By configuring the structure described above, the cosmetic liposome-containing composition of the present invention contains γ-aminobutyric acid and stably contains fine liposomes having a monolayer structure.

[0017] In the cosmetic liposome-containing composition of the present invention, as a component constituting the liposome, in addition to each of the components of polyoxyethylene phytosterol (component B), cholesterol (component C) and lecithin (component D), it further includes at least one compound E (component E) selected from the group consisting of phytosterol fatty acid esters and sphingosine bases. It is found that although the liposome is a liposome containing γ-aminobutyric acid (component A), it is stably contained in the composition as a fine liposome with an average particle size of 100 nm to 500 nm having a monolayer structure.

[0018] In Patent Document 1, liposomes equivalent to specific liposomes are not described.

[0019] In this invention, from the viewpoint of increasing the content of γ-aminobutyric acid and the excellent permeability of liposomes to the skin, the average particle size of the specific liposomes is 100nm to 500nm.

[0020] In this invention, whether a cosmetic liposome-containing composition contains liposomes with a monolayer structure is further confirmed by the percentage (%) of liposomes with a monolayer structure relative to the total number of liposomes contained in the liposome-containing composition (hereinafter also referred to as "liposome monolayer ratio (%)").

[0021] In this invention, from the viewpoint of increasing the content of γ-aminobutyric acid in specific liposomes, the monolayer percentage (%) of liposomes is more preferably 50% or more, more preferably 70% or more, and may also be 100%. More specifically, the monolayer percentage (%) of liposomes contained in the liposome-containing composition for cosmetic use is preferably 50% to 100%, and more preferably 70% to 100%. In this invention, when the monolayer percentage (%) of liposomes is 50% or more, it is determined that the cosmetic liposome-containing composition stably contains liposomes having a monolayer structure.

[0022] In addition, the cosmetic liposome-containing composition of the present invention may also contain liposomes with a multilayer structure (also known as multilayer endoplasmic reticulum) as liposomes.

[0023] In this invention, the monolayer percentage (%) of liposomes is determined as a percentage (%) calculated based on the following count: the count is obtained by observing the liposomes contained in the cosmetic liposome-containing composition in a frozen embedded state using a transmission electron microscope (hereinafter also referred to as TEM), and counting the total number of liposomes contained in the cosmetic liposome-containing composition and the total number of liposomes with a monolayer structure. More specifically, firstly, TEM was used to obtain TEM images of cosmetic liposome-containing compositions at a magnification of 50,000. In three randomly selected locations from TEM images, the total number of liposomes within a circle of 2 μm radius and the total number of liposomes with a monolayer structure were counted. Then, the monolayer percentage (%) was calculated based on the total number of liposomes and the total number of liposomes with a monolayer structure. In this invention, "liposome monolayer rate (%)" is set as the arithmetic mean of the monolayer rates (%) of the three sites calculated above.

[0024] In addition, the content of liposomes can be comprehensively evaluated by the "average particle size of liposomes" and the "unionization rate of liposomes (%)". For example, when comparing liposomes with a monolayer structure and liposomes with a multilayer structure, if the average particle size is the same, the area occupied by the lipid membrane portion within each size is smaller, thus the content of inclusions in liposomes with a monolayer structure is greater. Therefore, if the "average particle size of liposomes" is equal, the higher the value of the monolayer percentage (%), the higher the content of inclusions can be evaluated. Furthermore, when comparing liposomes with different monolayer structures, the larger the particle size, the greater the content of inclusions. Therefore, if the monolayer percentage (%) of liposomes is the same, the larger the "average particle size of the liposomes", the higher the content of inclusions in the liposomes can be evaluated.

[0025] In this invention, from the viewpoint of increasing the content of γ-aminobutyric acid and the excellent permeability of liposomes to the skin, the average particle size of the specific liposomes is 100nm to 500nm. The average particle size of the specific liposomes is more preferably 120 nm or more, further preferably 140 nm or more, and especially preferably 170 nm or more. Large-sized liposomes tend to aggregate and cluster over time, making them prone to multilayering. Therefore, from the viewpoint of improving the long-term stability of liposomes and maintaining their content, the average particle size of a specific liposome is more preferably 400 nm or less, more preferably 360 nm or more, and especially preferably 300 nm or less. Furthermore, having an average particle size of 400 nm or less tends to further enhance the permeability of liposomes to the skin and other materials. In summary, in a certain manner, the average particle size of a particular liposome is preferably 120 nm to 400 nm, more preferably 140 nm to 360 nm, and even more preferably 170 nm to 300 nm.

[0026] In this invention, the "average particle size" of liposomes refers to the volume average particle size obtained by dynamic light scattering method. Examples of particle size analyzers that utilize dynamic light scattering include the FPAR-1000 thick particle size analyzer (manufactured by Otsuka Electronics Co., Ltd.), the Nanotrac UPA (manufactured by Nikkiso Co., Ltd.), and the LB-550 dynamic light scattering particle size distribution measuring device (manufactured by HORIBA, Ltd.). The cosmetic liposome-containing composition was diluted 10 times by weight with pure water and the average particle size was determined at room temperature (25°C). In addition, "pure water" refers to pure water obtained through ultrapure water manufacturing equipment manufactured by Merck KGaA, etc. According to the dynamic light scattering method described above, the average particle size of liposomes contained in a cosmetic liposome-containing composition can be determined. Furthermore, cosmetic liposome-containing compositions sometimes contain particulate matter other than liposomes; even in this case, the average particle size determined by the above method is taken as the average particle size of the liposomes. Additionally, when the average particle size is determined by the above method, it can be filtered using a 230-mesh (pore size: 65 μm) filter before measurement.

[0027] In this invention, a specific liposome contains γ-aminobutyric acid (component A), polyoxyethylene phytosterol (component B), cholesterol (component C), lecithin (D), compound E (component E), and water.

[0028] Among the components contained in a particular liposome, γ-aminobutyric acid (component A) is preferably contained in the inclusions of the particular liposome (i.e., the inner aqueous phase) in a water-soluble state. The cosmetic liposome-containing composition of the present invention may contain γ-aminobutyric acid in the external aqueous solution (outer aqueous phase) of the liposome. It is speculated that among the components contained in a specific liposome, polyoxyethylene phytosterol (component B), cholesterol (component C), lecithin (component D) and compound E (component E) are contained in the lipid bilayer membrane that constitutes the specific liposome.

[0029] (γ-Aminobutyric acid: component A) The cosmetic liposome-containing composition of the present invention contains γ-aminobutyric acid (GABA) in specific liposomes. γ-aminobutyric acid is a water-soluble compound and is contained at least in the inclusions (inner aqueous phase) of the liposomes.

[0030] Gamma-aminobutyric acid (GABA) is an amino acid known to function as a neurotransmitter. It is known to contribute to various skin effects, including preventing skin aging through vasodilation, promoting collagen production, promoting hair growth, whitening the skin, promoting epidermal cell proliferation, and promoting hyaluronic acid production.

[0031] As for γ-aminobutyric acid, both commercially available products and synthetic products can be used. Examples of commercially available γ-aminobutyric acid (GABA) include Gabacare BL98T GABA (BLOOMAGEBIOTECHNOLOGY Corp., Ltd.) and GABA-Aminobutyric acid-lactobacillus type (IMCD Japan LLC). γ-Aminobutyric acid (GABA) can be a synthetic product manufactured according to known manufacturing methods. For example, GABA can be a substance produced by adding a solution containing glutamic acid and / or glutamate to plants and / or plant processed products, as described in Japanese Patent Application Publication No. 2013-194030, and reacting it with an enzymatic action of decarboxylglutamate enzyme present in the plant, from the glutamic acid in the above solution and the glutamic acid contained in the plant and / or plant processed products.

[0032] The content of γ-aminobutyric acid (GABA) relative to the total mass of the cosmetic liposome-containing composition can be appropriately set according to the target audience of the cosmetic liposome-containing composition. For example, the content of GABA relative to the total mass of the cosmetic liposome-containing composition can be set to 0.0001% by mass to 20% by mass.

[0033] (Polyoxyethylene phytosterols: Component B) Polyoxyethylene phytosterols are compounds composed of (CH2CH2-O) n The term refers to oxyvinyl phytosterols. In this invention, phytosterols include hydrogenated phytosterols (phytosterols). Specific examples of phytosterols include sitosterol, stigmasterol, fucosterol, spinasterol, brassosterol, and their hydrogenated derivatives.

[0034] From the viewpoint of increasing the content of inclusions, the average molar number of oxyethylene addition of polyoxyethylene phytosterols is preferably 5 or more, and more preferably 10 or more. Furthermore, by setting the average molar number of oxyethylene additions of polyoxyethylene phytosterols to 5 or more, the proportion of liposomes with monolayer structures (i.e., monolayer rate (%)) can be increased, which can further improve the content of liposome inclusions. From the viewpoint of increasing the content of inclusions, the average molar number of oxyethylene addition of polyoxyethylene phytosterols is preferably 5 to 30, more preferably 10 to 20. In addition, the average molar number of oxyethylene additions of polyoxyethylene phytosterols can be determined by known analytical methods such as high performance liquid chromatography (HPLC), but when using commercially available products, this value can be referenced if a catalog value is available.

[0035] As a polyoxyethylene phytosterol, it can be used in commercially available products. Examples of commercially available polyoxyethylene phytosterols include NIKKOL (registered trademark) BPS-5 (average molar addition of vinyl oxy group 5), NIKKOL (registered trademark) BPS-10 (average molar addition of vinyl oxy group 10), NIKKOL (registered trademark) BPS-20 (average molar addition of vinyl oxy group 20), NIKKOL (registered trademark) BPS-30 (average molar addition of vinyl oxy group 30), NIKKOL (registered trademark) BPSH-25 (average molar addition of vinyl oxy group 25, ethylene oxide adduct of hydrogenated phytosterol), and NIHON EMULSION, all manufactured by Nikko Chemicals Co., Ltd. EMLEX Co., Ltd. manufactures EMLEX PS-5 (average molar addition of vinyl oxytoluene 5), EMLEX PS-10 (average molar addition of vinyl oxytoluene 10), EMLEX PS-20 (average molar addition of vinyl oxytoluene 20), EMLEX PS-30 (average molar addition of vinyl oxytoluene 30), and EMLEX PS-25 (average molar addition of vinyl oxytoluene 25), etc.

[0036] The content of polyoxyethylene phytosterol in the cosmetic liposome-containing composition involved in this invention can be appropriately determined so that specific liposomes have a monolayer structure and an average particle size of 100 nm to 500 nm. The content of polyoxyethylene phytosterol relative to the total mass of the cosmetic liposome-containing composition can be 0.00005% to 0.25% by mass, or 0.05% to 0.20% by mass.

[0037] (Cholesterol: component C) In this invention, cholesterol includes cholesterol alcohol and cholesterol derivatives.

[0038] Examples of cholesterol include cholesterol, dihydrocholesterol, dehydrocholesterol, cholesterol oleate, cholesterol isostearate, cholesterol hydroxystearate, and polyoxyethylene cholesterol ether.

[0039] The cholesterol content in cosmetic liposome-containing compositions can be appropriately determined to give specific liposomes a monolayer structure and an average particle size of 100 nm to 500 nm. The cholesterol content relative to the total mass of the cosmetic liposome composition can be 0.003% to 0.5% by mass, or 0.1% to 0.20% by mass.

[0040] (Lecithin: Component D) Examples of lecithin include natural lecithin obtained from plants such as soybeans, rapeseed, sunflower, safflower, peanuts, cottonseed, corn, rice, and barley, as well as egg yolks, and their derivatives (hereinafter also referred to as lecithin derivatives). Examples of lecithin derivatives include hydrogenated lecithin, enzyme-treated lecithin (also known as lysophosphatidylcholine), and compounds obtained by introducing polyethylene glycol, amino polysaccharides, etc., into the phospholipids of lecithin. From the viewpoint of oxidative stability, hydrogenated lecithin is particularly preferred.

[0041] From the viewpoint of the long-term stability of liposome-containing compositions for cosmetic use, the content of phosphatidylcholine relative to the total mass of lecithin (hereinafter also referred to as PC content) is preferably 75% or more, more preferably 80% or more by mass, even more preferably 85% or more by mass, and particularly preferably 90% or more by mass. In addition, PC content can be determined by thin-layer chromatography / flame ionization detector (TLC / FID) or high-performance liquid chromatography (HPLC).

[0042] Lecithin can be found in commercially available products. Commercially available lecithin products include COATSOME NC-21 (PC content ≥ 90% by mass) manufactured by NOF CORPORATION and NIKKOL (registered trademark) Lecinol S-10E (PC content 75%–85% by mass) manufactured by Nikko Chemicals Co., Ltd.

[0043] The lecithin content in the cosmetic liposome-containing composition involved in this invention can be appropriately determined to satisfy the above-mentioned preferred embodiments. The lecithin content relative to the total mass of the cosmetic liposome composition can be 0.01% to 1.0% by mass, or 0.5% to 0.6% by mass.

[0044] =The quantitative relationship between component A and components B, C, and D= In the cosmetic liposome-containing composition of the present invention, the ratio of the content of γ-aminobutyric acid (component A) to the total content of polyoxyethylene phytosterol (component B), cholesterol (component C), and lecithin (component D) (A / (B+C+D)) is preferably 0.05 to 20.0 by mass, more preferably 0.1 to 20.0, further preferably 0.5 to 15, and even more preferably 1.0 to 13.0. If the ratio (A / (B+C+D)) is 0.1 to 20.0, the cosmetic liposome-containing composition can more stably contain fine liposomes with an average particle size of less than 500 nm.

[0045] (E: E component, which is a compound selected from at least one of the groups consisting of phytosterol fatty acid esters and sphingosine bases) In compound E, phytosterol fatty acid esters refer to esters of fatty acids and phytosterols. Phytosterol fatty acid esters can be esters of fatty acids with 12 to 22 carbon atoms and phytosterols. Phytosterol fatty acid esters can also be esters of a mixture of fatty acids with different carbon numbers and phytosterols. Phytosterol fatty acid esters are a preferred option.

[0046] In compound E, the sphingosine base refers to a long-chain aliphatic amine that is a component of sphingolipids and contains two or three hydroxyl groups at the end. Examples of sphingosine bases include phytosphingosine, dihydrosphingosine, sphingosine, hydroxysphingosine, and hexanosphingosine. Phytosphingosine is a preferred sphingosine base.

[0047] In this invention, a specific liposome as compound E may contain only one of phytosterol fatty acid esters and sphingosine bases, or it may contain both phytosterol fatty acid esters and sphingosine bases.

[0048] The content of compound E in the cosmetic liposome-containing composition of the present invention can be appropriately determined so that the specific liposomes have a monolayer structure and an average particle size of 100 nm to 500 nm. The content of compound E relative to the total mass of the cosmetic liposome composition can be 0.001% to 0.5% by mass, or 0.05% to 0.1% by mass.

[0049] In this invention, regarding the "content of compound E", When the compound corresponding to compound E is only a phytosterol fatty acid ester, the content of the phytosterol fatty acid ester is indicated. When the compound corresponding to compound E consists only of a sphingosine base, it indicates the content of the sphingosine base. When the compound corresponding to compound E contains both phytosterol fatty acid esters and sphingosine bases, it represents the sum of the contents of phytosterol fatty acid esters and sphingosine bases.

[0050] =The quantitative relationship between component A and component E= In the liposome-containing cosmetic composition of the present invention, the ratio (A / E) of the content of γ-aminobutyric acid (component A) to the content of compound E (component E) is preferably 0.4 to 1000 by mass, more preferably 2 to 400, and even more preferably 20 to 200. If the ratio (A / E) is 0.4 to 1000, the liposome-containing cosmetic composition exhibits excellent inhibition of precipitation and can more stably contain fine liposomes with an average particle size of 500 nm or less.

[0051] (Ergothioneine) The cosmetic liposome-containing compositions of the present invention may further contain ergothioneine. In this invention, the term "ergothioneine" includes ergothioneine and its derivatives. Ergothioneine is known as a component with antioxidant capabilities derived from natural sources.

[0052] Ergothione is known as a compound having the following structure.

[0053] [Chemical Formula 1]

[0054] The following shows the structure of ergothioneine derivatives.

[0055] [Chemical Formula 2]

[0056] In the above formula, X represents -O-R' or -NR'R", R, R', and R" independently represent a hydrogen atom, an alkyl group with 1 to 18 carbon atoms, an alkenyl group with 1 to 18 carbon atoms, or an acyl group with 1 to 18 carbon atoms, respectively. The above alkyl, alkenyl, or acyl groups can form salts. Alkyl groups can be straight-chain or branched. The aforementioned alkyl, alkenyl, or acyl groups can be substituted with hydroxyl groups, esterified hydroxyl groups, halogen atoms, carboxyl groups and their derivatives, amino groups and their derivatives, and may also contain heteroatoms in the chain, such as oxygen atoms or ionic atoms. β-hydroxyergothionein is included in ergothionein derivatives.

[0057] As ergothioneine, commercially available products are permitted. As commercially available ergothioneine, it can be used without special restrictions as long as it is a substance commonly used in pharmaceuticals, quasi-drugs, and cosmetics.

[0058] For example, ergothionein can be extracted from mushrooms of the Pleurotaceae family. Furthermore, ergothioneine can also be obtained using known methods such as fermentation and chemical synthesis. Among these, ergothioneine obtained from mushrooms is preferred from the perspective of being derived from natural sources and having high yield.

[0059] As commercially available products of ergothioneine, commercially available powders of ergothioneine or compositions containing pre-dissolved ergothioneine can also be used. Examples of commercially available products include L-Ergothioneine obtained from ASAHI TRADING CO., LTD., AntiOxd-Ex manufactured by Shenzhen Readline Biotech Co., Ltd., Bioyout (registered trademark)-EGT Pure ultra-high purity ergothioneine manufactured by BLOOMAGEBIOTECHNOLOGY Corp., Ltd., THIOTAINE manufactured by AGIDermatics, and Natural ERG Liquid manufactured by KOEI KOGYO Co., Ltd.

[0060] The cosmetic liposome-containing composition of the present invention may contain only one compound contained in ergothioneine, or it may contain two or more compounds contained in ergothioneine.

[0061] In the cosmetic liposome-containing composition of the present invention, there is no particular limitation on the content of ergothioneine, which can be appropriately selected according to the purpose. From the viewpoint of obtaining sufficient antioxidant effect, the content of ergothioneine relative to the total mass of the cosmetic liposome-containing composition is preferably 0.0001% to 1% by mass.

[0062] (water) The cosmetic liposome-containing composition involved in this invention contains water. Water is contained in liposome-containing compositions as one of the components of liposomes and as one of the components of the dispersion medium used to disperse liposomes in the composition. Water, as one of the components, and water contained in the dispersion medium can be categorized into ion-exchanged water, pure water, purified water, and tap water, among which purified water is preferred from the perspective of its suitability for cosmetics.

[0063] The content of water relative to the total mass of the cosmetic liposome-containing composition is not particularly limited, but is preferably 1% to 99% by mass, more preferably 10% to 95% by mass, and even more preferably 20% to 90% by mass. Furthermore, in this invention, "the content of water relative to the total mass of the cosmetic liposome-containing composition" means the sum of the content of water contained in the liposomes relative to the total mass of the cosmetic liposome-containing composition and the content of water contained in the dispersion medium relative to the total mass of the cosmetic liposome-containing composition.

[0064] (ethanol) From the viewpoint of facilitating the manufacture of liposomes, the cosmetic liposome-containing composition of the present invention preferably contains ethanol. Ethanol can be contained in the inclusions of liposomes (i.e., it can be contained within liposomes), in the dispersion medium, or in both the inclusions and the dispersion medium. As ethanol, any of those that can be obtained as ethanol or anhydrous ethanol can be used.

[0065] From the viewpoint of the long-term stability of liposomes, the content of ethanol relative to the total mass of the cosmetic liposome-containing composition is preferably 0.2% to 30% by mass. Furthermore, the content of ethanol relative to the total mass of the cosmetic liposome-containing composition can be 1% or more by mass, 3% or more by mass, or 5% or more by mass. Furthermore, the content of ethanol relative to the total mass of the cosmetic liposome-containing composition may be less than 25% by mass, less than 20% by mass, or less than 15% by mass. Furthermore, in this invention, "the content of ethanol relative to the total mass of the cosmetic liposome-containing composition" means the sum of the content of ethanol contained in the liposomes relative to the total mass of the cosmetic liposome-containing composition and the content of ethanol contained in the dispersion medium relative to the total mass of the cosmetic liposome-containing composition.

[0066] (beauty ingredients) In this invention, "cosmetic ingredient" refers to an ingredient that acts on the skin and other parts of the body and can exert a cosmetic effect, indicating an active ingredient used in cosmetics and the like. Gamma-aminobutyric acid (component A) and ergothioneine, which have already been described, can function as cosmetic ingredients.

[0067] The cosmetic liposome-containing composition of this invention may contain other cosmetic ingredients besides γ-aminobutyric acid (component A) and ergothioneine. These other cosmetic ingredients may be contained within the liposomes (inner aqueous phase) or on the outside of the liposomes (outer aqueous phase).

[0068] As other beauty ingredients, it can be used in the field of cosmetics (i.e., cosmetics and quasi-drugs (e.g., medicated cosmetics)).

[0069] As cosmetic ingredients, specific examples include tranexamic acid, Sanguisorba officinalis extract, ascorbic acid, ascorbate stearate, sodium ascorbate, disodium ascorbate sulfate, aspartic acid, aspartame, acetylglucosamine, acetylglutamic acid, acetylcysteine, acetylacetonine ethyl ester, disodium adenosine triphosphate, disodium adenosine monophosphate, ε-aminocaproic acid, allantoin, allantoin-β-glycyrrhetinic acid, albumin, inositol, erythritol, and amino hydrochloride. Glucosamine, Pyridoxine Hydrochloride, Hydroxyproline, Orotic Acid, Hydrolyzed Elastin, Caffeine Hydrate, Chondroitin Sulfate Sodium, Cyanocobalamin, Water-Soluble Elastin, Taurine, Sodium Palmitoyl Methyl Taurate, Sodium Myristoyl Methyl Taurate, Thiamine Hydrochloride, Theanine, Deoxyribonucleic Acid, Ascorbyl Palmitate, Panthenol, Sodium Pantothenate, Calcium Pantothenate, Pyridoxine, Phytic Acid, Placental Extract, Flavin Adenine Dinucleotide Disodium Dihydrate, Anhydrous Caffeine Caffeine, riboflavin, riboflavin butyrate, riboflavin phosphate, resorcinol, acetylpropionic acid, glycine, arginine, lysine solution, lauroyl lysine, palmitoyl aspartic acid, cysteine, methionine, glutamic acid, threonine, serine, tyrosine, histidine, proline, glutathione, salicylic acid, nicotinamide, retinyl palmitate, alginic acid, γ-undecyl lactone, perilla oil, estradiol, estrone, ergocalcisterol, β-carotene, glucosamine, cholecalciferol, tocopherol acetate, retinyl acetate, shikonin, ascorbate dipalmitate, pyridoxine dipalmitate, natural vitamin E, α-tocopherol, horse oil, γ-nonalactone, bisabolol, vitamin A oil, cypress thiol, fumaric acid, powdered vitamin A, tocopherol linoleate, δ-tocopherol, isoleucine, phenylalanine, valine, leucine, ascorbate tetra-2-hexyldecanoate, etc. In addition, caffeine includes anhydrous caffeine.

[0070] From the viewpoint of solubility of the contents and dispersion medium of liposomes, the other cosmetic ingredients mentioned above are preferably water-soluble cosmetic ingredients. The types and amounts of other beauty ingredients can be set appropriately according to the purpose.

[0071] (Other ingredients) The cosmetic liposome-containing composition involved in this invention may also contain other ingredients such as physiological saline, sugar, pH adjuster, and preservative. Examples of sugars include glucose, fructose, lactose, sucrose, trehalose, lactulose, and maltitol. Examples of pH adjusters include sodium hydrogen phosphate, sodium dihydrogen phosphate, anhydrous disodium hydrogen phosphate, sodium hydroxide (caustic soda), citric acid, acetic acid, and triethanolamine. Examples of preservatives include methylparaben.

[0072] The pH of the liposome inclusions and dispersion medium is not particularly limited, but is preferably 5 to 9, more preferably 7 to 8. The pH of the inclusions and dispersion medium can be adjusted by using the aforementioned pH adjuster.

[0073] [Manufacturing Method] The following describes a method for manufacturing a liposome-containing composition for cosmetic use, but it is not limited thereto. The cosmetic liposome-containing composition of the present invention can be manufactured by separately preparing an oil phase composition and an aqueous phase composition, mixing the obtained oil phase composition and aqueous phase composition, and then stirring and emulsifying them to form liposomes.

[0074] By mixing, stirring, and emulsifying an oil-phase composition and an aqueous-phase composition to form an O / W (oil-in-water) emulsion, a liposome-containing composition for cosmetics according to the present invention, comprising liposomes and a dispersion medium, is manufactured.

[0075] As a stirring method, ultrasound or mechanical shearing force can be used. Furthermore, to achieve uniform particle size, extrusion processing or microfluidic processing via a filter with a constant pore size can be performed. Through extrusion processing or similar methods, multi-capsule liposomes containing multiple individual liposomes can be separated into multiple individual liposomes.

[0076] The liquid temperature of the mixture can be adjusted appropriately, but it is preferred to set it to a temperature higher than the phase transition temperature of the lecithin contained in the mixture, for example, preferably 35°C to 70°C.

[0077] In the manufacture of the cosmetic liposome-containing composition according to the present invention, organic solvents and water can be evaporated from the composition after liposome formation (i.e., the composition containing liposomes). The aforementioned evaporation includes either intentionally causing part or all of the organic solvent and water to evaporate, or causing part or all of the organic solvent and water to evaporate naturally during stirring and emulsification.

[0078] When organic solvents and water are intentionally evaporated, the evaporation method is not particularly limited. Examples include heating organic solvents and water, allowing liposome-containing cosmetic compositions to stand, stirring liposome-containing cosmetic compositions, and vacuum degassing.

[0079] The method of containing inclusions (e.g., cosmetic ingredients) in liposomes is not particularly limited and can be carried out by using an aqueous composition in which the cosmetic ingredients are dissolved during emulsification.

[0080] The obtained cosmetic liposome-containing compositions can be processed using methods such as dialysis, filtration, and extrusion to ensure uniform average particle size of the contained liposomes. Extrusion involves passing the cosmetic liposome-containing composition through a fine-pore filter, applying physical shear force to achieve micronization. By maintaining the cosmetic liposome-containing composition and the filter at a temperature above the phase transition temperature of lecithin during the passage of the composition, rapid micronization can be achieved.

[0081] "cosmetic" The cosmetics involved in this invention are made using the above-described liposome-containing composition for cosmetics involved in this invention. The cosmetics involved in this invention may include, or may consist entirely of, the liposome-containing cosmetic compositions of this invention described above. That is, the liposome-containing cosmetic compositions of this invention described above can be directly used as cosmetics. When the cosmetics involved in this invention include the above-mentioned liposome-containing composition for cosmetics involved in this invention as a part thereof, the content of the liposome-containing composition for cosmetics involved in this invention may be selected from 0.1% to 10% by mass or 1% to 2% by mass relative to the total mass of the cosmetics involved in this invention.

[0082] The form of the cosmetics involved in this invention is not particularly limited. They can be liquid, jelly, gel, cream, solid (such as sticks), or semi-solid. Examples of uses for cosmetics involved in this invention include skin care cosmetics (lotions, lotions, serums, sunscreens, masks, etc.), body cosmetics (body lotions, body sunscreens, etc.), and scalp cosmetics, but are not limited to these. According to the above-described manner and uses, the cosmetics involved in this invention can contain ingredients other than the liposome-containing compositions for cosmetics involved in this invention. Example

[0083] The above embodiments will be described in more detail below through examples, but the above embodiments are not limited to these examples.

[0084] <Example 1> (Preparation of oil phase composition) Polyoxyethylene phytosterol (average addition molar number of oxyethylene: 20), hydrogenated lecithin (hydrogenated soybean lecithin, PC content above 90%), cholesterol, ascorbic acid tetra-2-hexyldecanoate, phytosterol oleate and anhydrous ethanol were mixed and dissolved by heating at 60°C for 10 minutes to obtain oil phase composition X.

[0085] (Preparation of aqueous phase composition) An aqueous composition Y-1 was obtained by mixing anhydrous disodium hydrogen phosphate, sodium dihydrogen phosphate, γ-aminobutyric acid and purified water, and heating at 60°C for 10 minutes to dissolve them. Furthermore, methylparaben and purified water were mixed and dissolved by heating at 60°C for 10 minutes to obtain an aqueous composition Y-2.

[0086] (Manufacturing of liposome-containing compositions for cosmetic use) While maintaining the aqueous phase composition Y-1 obtained above at 60°C, the oil phase composition X was added to the aqueous phase composition Y-1 after stirring at 3400 rpm (revolutions per minute) using a homogenizer. After addition, the mixture of aqueous phase composition Y-1 and oil phase composition X was stirred at 3400 rpm for 45 minutes. Aqueous phase composition Y-2 was then added to the stirred mixture, and the mixture was stirred uniformly for 5 minutes, followed by cooling to below 5°C for 35 minutes. After cooling, the mixture was filtered through a 230-mesh filter cloth to obtain a cosmetic composition (a liposome-containing composition for cosmetics). In addition, the contents of each component in the cosmetic composition (cosmetic composition containing liposomes) are shown in Table 1.

[0087] <Examples 2 to 9> The composition of the cosmetic composition was changed as shown in Table 1, except that the cosmetic composition (liposome-containing composition for cosmetic use) was manufactured in the same manner as in Example 1.

[0088] <Comparative Examples 1 to 15> The composition of the cosmetic composition was changed as shown in Table 2, except that the cosmetic composition (liposome-containing composition for cosmetic use) was manufactured in the same manner as in Example 1.

[0089] [evaluate] The cosmetic compositions manufactured in each example were evaluated as shown in Evaluation 1 and Evaluation 2 below. Cosmetic compositions for which both Evaluation 1 and Evaluation 2 are excellent are determined to be cosmetic compositions containing γ-aminobutyric acid and stably containing fine liposomes having a monolayer structure.

[0090] <<Evaluation 1: Monolayer ratio (the proportion of liposomes with a monolayer structure)>> The liposomes contained in the cosmetic compositions manufactured in each example were obtained at 50,000x magnification using a transmission electron microscope under a frozen embedded state.

[0091] At any three randomly selected locations from the TEM image, the total number of liposomes present within a circle with a radius of 2 μm and the total number of liposomes with a monolayer structure were counted. The average ratio of the total number of liposomes with a monolayer structure to the total number of liposomes contained in the cosmetic liposome-containing composition was evaluated according to the following evaluation criteria. A higher monolayer ratio (the proportion of liposomes with a monolayer structure) is preferred. Specifically, grades "A" and "B" are preferred, with grade "A" being the most preferred. (Evaluation Criteria) A: The single-layer rate is over 70%. B: The single-layer ratio is above 50% but less than 70%. C: The single-layer ratio is above 30% but less than 50%. D: The single-layer ratio exceeds 0% and is less than 30%. E: Monolayer rate 0% (no liposomes with monolayer structure were observed).

[0092] <<Evaluation 2: Average Particle Size of Liposomes>> The cosmetic compositions manufactured in each example were diluted 10 times their mass with pure water, and the volume average particle size of the contained liposomes was determined by dynamic light scattering using a thick-film particle size analyzer FPAR-1000 (manufactured by Otsuka Electronics Co., Ltd.). Furthermore, the volume average particle size determination was performed within 20 to 24 hours after manufacturing the cosmetic composition. The ambient temperature for the determination was set to 25°C. The obtained average particle size measurements were evaluated based on the following evaluation criteria. The measured values ​​and evaluation results of the average particle size of liposomes are shown in Table 1 or Table 2. The average particle size of the liposomes needs to be in the "A" or "B" grade, with "A" being the preferred grade. (Evaluation Criteria) A: The average particle size is greater than 100nm and less than 300nm. B: The average particle size is above 300nm and below 500nm. C: Average particle size exceeds 500 nm and is less than 7000 nm. D: Average particle size less than 100nm or greater than 700nm.

[0093] The composition and evaluation results of the cosmetic compositions manufactured in each example are shown in Tables 1 and 2 below. In Tables 1 and 2, empty columns in the composition column indicate that the corresponding component is not present. In Tables 1 and 2, “A / (B+C+D)” represents the ratio of the content of γ-aminobutyric acid to the total content of polyoxyethylene phytosterols, cholesterol and lecithin. In Table 1, "A / E" represents the ratio of the content of γ-aminobutyric acid to the content of compound E. In Table 2, the "-" in the "A / E" column indicates that the cosmetic composition does not contain compound E, therefore "A / E" cannot be calculated. In Table 2, the “-” in the monolayer ratio column indicates that the average particle size clearly exceeds 500 nm, therefore “Evaluation 1: Monolayer Ratio” was not performed.

[0094] [Table 1]

[0095] [Table 2]

[0096] As shown in Table 1, the cosmetic compositions of Examples 1 to 9 were confirmed to be the following cosmetic compositions: the average particle size of the liposomes was in the range of 100 nm to 500 nm, and the monolayer ratio was grade A or B, containing γ-aminobutyric acid, and stably containing fine liposomes with a monolayer structure.

[0097] As shown in Table 2, Comparative Examples 1, 8 to 15 (which do not contain compound E), Comparative Examples 2 and 3 (which use stearic acid instead of compound E), and Comparative Example 4 (which uses stearyl alcohol instead of compound E) are all cosmetic compositions containing liposomes with an average particle size of more than 700 nm. Furthermore, as shown in Table 2, Comparative Example 5, which used oleic acid instead of compound E, Comparative Example 6, and Comparative Example 7, which used isostearic acid instead of compound E, all contained liposomes with an average particle size of less than 100 nm and had a low monolayer ratio.

[0098] The detailed information of the components shown in Tables 1 and 2 is as follows.

[0099] (Oil phase composition) • Polyoxyethylene phytosterols (Product name: Nikkol (registered trademark) BPS-20, Nikko Chemicals Co., Ltd., Ingredient B) • Cholesterol (Product Name: Cholesterol JSQI, NIPPON FINE CHEMICAL CO., LTD., C component) • Hydrogenated lecithin (hydrogenated soybean lecithin, PC content over 90%, component D) Phytosphingosine (product name: Phytosphingosine, Evonik, ingredient E) • Stearic acid (product name: LUNAC S-98, Kao Corporation, comparative compound of component E) • Stearyl alcohol (Product name: Stearyl alcohol NX, KOKYU ALCOHOL KOGYO CO., LTD., Comparative compound of component E) • Oleic acid (Product name: LUNAC OV, Kao Corporation, comparative compound of component E) • Isostearic acid (Product name: Isostearic acid EX, KOKYU ALCOHOL KOGYO CO., LTD., comparative compound of component E) • Ascorbic acid tetra-2-hexyldecanoate (NIKKOL (registered trademark) VC-IP, Nikko Chemicals Co., Ltd., other cosmetic ingredients)

[0100] (Aqueous phase composition) ·γ-Aminobutyric acid (product name: Gabacare) TM BL98T Aminobutyric acid, BLOOMAGEBIOTECHNOLOGY Corp., Ltd., ingredient A) Ergothioneine raw material (product name: Natural_ERG_Liquid, KOEI KOGYO Co., Ltd., ergothioneine concentration: 0.03% by mass) Water (purified water)

Claims

1. A liposome-containing composition for cosmetic use, comprising liposomes and water, wherein, The liposomes comprise γ-aminobutyric acid, polyoxyethylene phytosterol, cholesterol, lecithin, and compound E, which is selected from the group consisting of at least one of phytosterol fatty acid esters and sphingosine bases, and comprise liposomes having a monolayer structure with an average particle size of 100 nm to 500 nm.

2. The liposome-containing composition for cosmetic use according to claim 1, wherein, The ratio of γ-aminobutyric acid content to compound E content is 0.4 to 1000 on a mass basis.

3. The liposome-containing composition for cosmetic use according to claim 1 or 2, wherein, The ratio of γ-aminobutyric acid content to the total content of polyoxyethylene phytosterols, cholesterol and lecithin is 0.05 to 20.0 on a mass basis.

4. The cosmetic liposome-containing composition according to claim 1 or 2, further comprising ergothioneine.

5. A cosmetic product made using any one of the cosmetic compositions containing liposomes according to claims 1 to 4.

Images